University of the Witwatersrand Helen Joseph (WITS HJH)
Welcome,         Profile    Billing    Logout  
 7 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Avihingsanon, Anchalee
NCT03785106: Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

Active, not recruiting
3
2500
RoW
Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6), Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
The HIV Netherlands Australia Thailand Research Collaboration, King Chulalongkorn Memorial Hospital, Police General Hospital, Pranangklao Hospital, Taksin Hospital, Bhumibol Adulyadej Hospital, Klang Hospital, Chiang Rai Prachanukroh Hospital, Sanpatong Hospital, Queen Sawang Vadhana Memorial Hospital, Buddhachinnaraj Hospital, Maharat Nakhon Ratchasima Hospital, HatYai Hospital, Srinagarind Hospital, Khon Kaen University, Sisaket Hospital, The Public Health Centre 28 Krung thon buri
HIV-infected Participants With Latent TB Infection in High TB Burden Country
03/38
03/38
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
INSIGHT12, NCT04910269 / 2021-001663-24: Outpatient Treatment With Anti-Coronavirus Immunoglobulin

Recruiting
3
820
Europe, US, RoW
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
COVID, SARS-CoV2 Infection, Covid19
08/26
08/26
NCT05343481: Efficacy of VTP-300 in Chronic Hepatitis B Infection

Active, not recruiting
2
120
RoW
ChAdOx1-HBV, MVA-HBV, Nivolumab, Opdivo 10mg/ml concentrate for solution for infusion
Barinthus Biotherapeutics
Chronic Hepatitis B
02/25
10/26
NCT03731559: Efficacy, Safety and Pharmacokinetics of DTG with RIF

Recruiting
2
200
RoW
DTG 50 mg OD with food, DTG 50 mg BID
The HIV Netherlands Australia Thailand Research Collaboration, Chest Division, Chulalongkorn University, Infectious Disease, Chulalongkorn University, Bamrasnaradura Infectious Diseases Institute, Bhumibol Adulyadej Hospital, Infectious Disease Taksin Hospital, Klang Hospital, Infectious Disease Chiangrai Prachanukroh Hospital, Infectious Disease Chonburi Hospital, Infectious Disease Buddhachinaraj Phitsanulok Hospital, Radboud University Medical Center, Department of Disease Control, Ministry of Public Health (MOPH), Thailand
HIV/TB Coinfection
06/25
06/25
NCT05330455: Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection

Recruiting
2
132
Europe, Canada, RoW
GSK3965193, Placebo to match GSK3965193, Bepirovirsen
GlaxoSmithKline
Hepatitis B
10/27
10/27
NCT05276297 / 2021-003567-10: A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy

Active, not recruiting
2
184
Europe, RoW
GSK3228836, Bepirovirsen, GSK3528869A, Control
GlaxoSmithKline, GlaxoSmithKline Biologicals
Hepatitis B, Chronic
02/26
02/26
B-Sure, NCT04954859 / 2021-000554-26: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants

Recruiting
2
450
Europe, Canada, Japan, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Hepatitis B
02/29
02/29
NCT03866187 / 2017-001452-55: Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

Terminated
1/2
135
Europe, RoW
ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation, HBc-HBs/AS01B-4 high dose formulation, MVA-HBV low dose formulation, MVA-HBV high dose formulation, Placebo
GlaxoSmithKline, GlaxoSmithKline Biologicals
Hepatitis B, Chronic
10/24
10/24
NCT04552015: Microneedles for Diagnosis of LTBI

Terminated
N/A
4
RoW
TST vs PPD microneedle test
The HIV Netherlands Australia Thailand Research Collaboration, National Nanotechnology Center (NANOTEC), The National Science and Technology Development Agency (NSTDA)
Latent Tuberculosis
10/22
10/22
NCT05350865: Thailand HDV Cohort

Recruiting
N/A
3152
RoW
The HIV Netherlands Australia Thailand Research Collaboration, King Chulalongkorn Memorial Hospital, Thai Red Cross AIDS Research Centre, Siriraj Hospital, Taksin Hospital, Gilead Sciences
HDV
05/25
05/25
Badal-Faesen, Sharlaa
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
B-Focus, NCT06497504: Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection

Recruiting
2
150
Europe, Canada, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline
Hepatitis B
01/27
05/27

Download Options